Obsessive-Compulsive Disorder Clinical Trial
Official title:
Effectiveness of the Immersive Virtual Reality (VR) Treatment With Cognitive Behaviour Therapy (CBT) for Obsessive-Compulsive Disorder (OCD) : A Randomized Controlled Study
This study will evaluate the clinical effectiveness ofthe Immersive Virtual Reality alongside exprosure and response Prevention (ERP) Treatment in cognitive-Behavioral Therapy for Obsessive-compulsive Disorder, and the underlying neural mechanism by electroencephalography (EEG) and eye-tracking methodology .
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - age: 18-50 years old; - Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for OCD; - Y-BOCS total score > or = 16, discontinued medication for at least 8 weeks before - the enrollment or the paitients' clinical medication is stable for at least a month (the dose and the types of drugs) .>or=9 years education Exclusion Criteria: - Any axis I psychiatric disorder comorbidity - Participants who have received any forms of psychological therapy in the past. - Patients cannot tolerate or adapt to the somatic discomfort caused by VR . - Prior history of neurological disease (e.g., epilepsy) or brain surgery for traumatic brain injury - Participants with claustrophobic, heart pacemaker, mechanical heart valve, mechanical implant such as an aneurysm clip, hip replacement, or any other pieces of metal that have accidentally entered their body. - Any current significant medical condition. - serious suicide risk |
Country | Name | City | State |
---|---|---|---|
China | Shanghai Mental Health Center | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai Mental Health Center |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Yale-Brown Obsessive Compulsive Scale(Y-BOCS) score | It assesses the severity of OCD symptoms. The Y-BOCS scale ranges from 0 to 40, with 0 being no symptoms and 40 being severe.The responder on Y-BOCS is defined as a Y-BOCS decrease at least 35% from the baseline at post-treatment. | from baseline to 8weeks | |
Secondary | Change in Obsessive Compulsive Inventory-Revised(OCI-R) | It is an inventory of OCD symptoms with 18 items that are rated on a 5-point Likert scale. Total scores range from 0 to 72, with higher scores indicating more severe OCD symptoms. | from baseline to 8weeks | |
Secondary | Change in Beck Depression Inventory(BDI) | It consists of 21 items and uses a 0 to 3 severity scale. Total scores range from 0 to 63, with higher scores indicating more severe depression symptoms. | from baseline to 8weeks | |
Secondary | Change in Beck Anxiety Inventory (BAI) | It is an inventory of anxiety symptoms with 18 items that are rated on a 5-point Likert scale(0 to 4). Total scores range from 0 to 72, with higher scores indicating more severe anxiety symptoms. | from baseline to 8weeks | |
Secondary | Chinese version of Working Alliance Inventory-Short Form (WAI-SR) | The WAI-SR measures three domains of the therapeutic alliance: (a) agreement between patient and therapist on the goals of the treatment (Goal); (b) agreement between patient and therapist about the tasks to achieve these goals (Task); and (c) the quality of the bond between the patient and therapist (Bond). | assessed only once after the entire treatment at the end of the eighth week. (at the end week 8 ) | |
Secondary | Simulator Sickness Questionnaire(SSQ) | The SSQ has been traditionally used for simulator motion sickness measurement,The SSQ was administered immediately after each task, and the order of work was determined using the Latin square design. | The SSQ should be assessed each time after the VR+ERP treating for OCD patients. (at week 2, 3, 4, 5, 6, 7) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04934007 -
Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder
|
N/A | |
Recruiting |
NCT04071990 -
Family Involvement in CBGT of OCD: a Randomized Controlled Trial
|
N/A | |
Completed |
NCT02541968 -
Internet-based vs Face-to-face Cognitive Behavioural Therapy for Obsessive-compulsive Disorder
|
N/A | |
Recruiting |
NCT05651295 -
A Precision Medicine Approach to Target Engagement for Emotion Regulation
|
N/A | |
Recruiting |
NCT05391503 -
Light Therapy for Obsessive-compulsive Disorder (OCD)
|
N/A | |
Recruiting |
NCT04539951 -
Pragmatic Trial of Obsessive-compulsive Disorder
|
Phase 2 | |
Completed |
NCT03416504 -
Methods for Managing Intrusive Thoughts
|
N/A | |
Not yet recruiting |
NCT06029738 -
Effect on Obsessive-Compulsive Beliefs and Symptoms of MCT-OCD
|
N/A | |
Recruiting |
NCT02844049 -
European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS
|
N/A | |
Terminated |
NCT02909660 -
What Are You Looking for? Psychometric and Experimental Analyses of Reassurance Seeking in Obsessive-compulsive Disorder
|
N/A | |
Completed |
NCT02911324 -
Cannabinoid Medication for Adults With OCD
|
Phase 1/Phase 2 | |
Completed |
NCT02217995 -
Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients
|
N/A | |
Terminated |
NCT02234011 -
A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder
|
Phase 2 | |
Withdrawn |
NCT01953042 -
Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders
|
N/A | |
Completed |
NCT02655926 -
Deep Brain Stimulation for Severe Obsessive Compulsive Disorder
|
N/A | |
Terminated |
NCT00758966 -
Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder
|
Phase 2 | |
Completed |
NCT04919785 -
Deep Brain Stimulation in Severe Obsessive-compulsive Disorder
|
N/A | |
Completed |
NCT00742664 -
Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project
|
Phase 1/Phase 2 | |
Completed |
NCT00523718 -
Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder
|
Phase 2 | |
Completed |
NCT00074815 -
Treatment of Obsessive Compulsive Disorder in Children
|
Phase 3 |